240 related articles for article (PubMed ID: 29127736)
21. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
Yoshikawa T; Ide T; Shimano H; Yahagi N; Amemiya-Kudo M; Matsuzaka T; Yatoh S; Kitamine T; Okazaki H; Tamura Y; Sekiya M; Takahashi A; Hasty AH; Sato R; Sone H; Osuga J; Ishibashi S; Yamada N
Mol Endocrinol; 2003 Jul; 17(7):1240-54. PubMed ID: 12730331
[TBL] [Abstract][Full Text] [Related]
22. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR.
Mitro N; Vargas L; Romeo R; Koder A; Saez E
FEBS Lett; 2007 May; 581(9):1721-6. PubMed ID: 17418145
[TBL] [Abstract][Full Text] [Related]
23. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
24. Activation of liver X receptors inhibits cadmium-induced apoptosis of human renal proximal tubular cells.
Fongsupa S; Soodvilai S; Muanprasat C; Chatsudthipong V; Soodvilai S
Toxicol Lett; 2015 Aug; 236(3):145-53. PubMed ID: 25980575
[TBL] [Abstract][Full Text] [Related]
25. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
Ogihara T; Chuang JC; Vestermark GL; Garmey JC; Ketchum RJ; Huang X; Brayman KL; Thorner MO; Repa JJ; Mirmira RG; Evans-Molina C
J Biol Chem; 2010 Feb; 285(8):5392-404. PubMed ID: 20007976
[TBL] [Abstract][Full Text] [Related]
26. Liver X receptors (LXR) as therapeutic targets in dyslipidemia.
Bełtowski J
Cardiovasc Ther; 2008; 26(4):297-316. PubMed ID: 19035881
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity.
Kim KH; Lee GY; Kim JI; Ham M; Won Lee J; Kim JB
J Lipid Res; 2010 Dec; 51(12):3425-33. PubMed ID: 20847297
[TBL] [Abstract][Full Text] [Related]
28. Ligand, receptor, and cell type-dependent regulation of ABCA1 and ABCG1 mRNA in prostate cancer epithelial cells.
Trasino SE; Kim YS; Wang TT
Mol Cancer Ther; 2009 Jul; 8(7):1934-45. PubMed ID: 19531574
[TBL] [Abstract][Full Text] [Related]
29. Adipocyte fatty acid-binding protein (aP2), a newly identified LXR target gene, is induced by LXR agonists in human THP-1 cells.
Liu QY; Quinet E; Nambi P
Mol Cell Biochem; 2007 Aug; 302(1-2):203-13. PubMed ID: 17396233
[TBL] [Abstract][Full Text] [Related]
30. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
31. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells.
Wente W; Brenner MB; Zitzer H; Gromada J; Efanov AM
Endocrinology; 2007 Apr; 148(4):1843-9. PubMed ID: 17194744
[TBL] [Abstract][Full Text] [Related]
32. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.
Thomas J; Bramlett KS; Montrose C; Foxworthy P; Eacho PI; McCann D; Cao G; Kiefer A; McCowan J; Yu KL; Grese T; Chin WW; Burris TP; Michael LF
J Biol Chem; 2003 Jan; 278(4):2403-10. PubMed ID: 12441342
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists.
Drouineaud V; Sagot P; Garrido C; Logette E; Deckert V; Gambert P; Jimenez C; Staels B; Lagrost L; Masson D
Mol Hum Reprod; 2007 Jun; 13(6):373-9. PubMed ID: 17449538
[TBL] [Abstract][Full Text] [Related]
34. Activation of liver X receptor enhances the proliferation and migration of endothelial progenitor cells and promotes vascular repair through PI3K/Akt/eNOS signaling pathway activation.
Yu J; Wang Q; Wang H; Lu W; Li W; Qin Z; Huang L
Vascul Pharmacol; 2014 Sep; 62(3):150-61. PubMed ID: 24892989
[TBL] [Abstract][Full Text] [Related]
35. Liver X receptors (LXRs) regulate apolipoprotein AIV-implications of the antiatherosclerotic effect of LXR agonists.
Liang Y; Jiang XC; Liu R; Liang G; Beyer TP; Gao H; Ryan TP; Dan Li S; Eacho PI; Cao G
Mol Endocrinol; 2004 Aug; 18(8):2000-10. PubMed ID: 15131258
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
[TBL] [Abstract][Full Text] [Related]
37. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms.
Morello F; Saglio E; Noghero A; Schiavone D; Williams TA; Verhovez A; Bussolino F; Veglio F; Mulatero P
Atherosclerosis; 2009 Nov; 207(1):38-44. PubMed ID: 19426978
[TBL] [Abstract][Full Text] [Related]
38. Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway.
Youlin K; Li Z; Weiyang H; Jian K; Siming L; Xin G
Pathol Res Pract; 2017 Mar; 213(3):267-270. PubMed ID: 28139275
[TBL] [Abstract][Full Text] [Related]
39. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
Zheng F; Zhang S; Lu W; Wu F; Yin X; Yu D; Pan Q; Li H
PLoS One; 2014; 9(6):e101269. PubMed ID: 24972069
[TBL] [Abstract][Full Text] [Related]
40. 1α-Hydroxy derivatives of 7-dehydrocholesterol are selective liver X receptor modulators.
Endo-Umeda K; Aoyama A; Shimizu M; Ishikawa M; Hashimoto Y; Yamada S; Makishima M
J Steroid Biochem Mol Biol; 2017 Sep; 172():136-148. PubMed ID: 28736297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
